Sign Out
Effect on weight gain/edema may be additive with the thiazolidinedione class of antidiabetic agents, use caution when coadministering these agents, particularly in patients with prior cardiovascular disease.
There have been postmarketing reports of hypersensitivity reactions (skin redness, blisters, hives, rash, dyspnea, and wheezing), including cases of angioedema. Discontinue pregabalin immediately in patients with these symptoms.
Pregabalin may cause somnolence/sedation and dizziness. Advise patients to not drive a car or operate other complex machinery until they have gained the ability to assess whether this medication impairs their ability to drive or perform other tasks.
Visual disturbances (blurred vision, decreased acuity and visual field changes) have been associated with pregabalin therapy, inform patients to notify their physician if changes in visual occur.
Pregabalin has been associated with discontinuation symptoms including insomnia, nausea, headache, anxiety, hyperhidrosis, and diarrhea following abrupt cessation and increases in seizure frequency (when used as an epileptic) may occur.
Pregabalin is not known to be active at receptor sites associated with drugs of abuse. As with any CNS active drugs, clinicians should carefully evaluate patients for history of drug abuse and observe them for signs of pregabalin misuse or abuse (e.g., development of tolerance, dose escalation, drug-seeking behavior).
The risk of toxic reactions to pregabalin may be greater in patients with impaired renal function. Take care in dose selection and adjust dose based on CrCl values in these patients.
